These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 18610798)
1. Neuroprotective trials: no longer a cautious optimism. Friedman JH Med Health R I; 2008 Jun; 91(6):158. PubMed ID: 18610798 [No Abstract] [Full Text] [Related]
2. [Treatments in the early stage of Parkinson disease]. Rascol O Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F77-84. PubMed ID: 18680822 [No Abstract] [Full Text] [Related]
3. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Schapira AH; Olanow CW Ann Neurol; 2003; 53 Suppl 3():S149-57; discussion S157-9. PubMed ID: 12666106 [No Abstract] [Full Text] [Related]
4. Neuroprotective therapy in Parkinson disease. Chen S; Le W Am J Ther; 2006; 13(5):445-57. PubMed ID: 16988541 [TBL] [Abstract][Full Text] [Related]
5. An overview of novel therapies for Parkinson's disease. Fahn S Exp Neurol; 1997 Mar; 144(1):21-3. PubMed ID: 9126146 [No Abstract] [Full Text] [Related]
7. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Schapira AH Neurology; 2009 Feb; 72(7 Suppl):S44-50. PubMed ID: 19221314 [TBL] [Abstract][Full Text] [Related]
8. I can't get no satisfaction: still no neuroprotection for Parkinson disease. Ahlskog JE Neurology; 2007 Oct; 69(15):1476-7. PubMed ID: 17923609 [No Abstract] [Full Text] [Related]
9. Beating a dead horse: dopamine and Parkinson disease. Tarsy D; Simon DK Neurology; 2008 Nov; 71(20):1651; author reply 1651-2. PubMed ID: 19001260 [No Abstract] [Full Text] [Related]
11. Treatment of early Parkinson's disease. Part 2. Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D Eur Neurol; 2009; 61(4):206-15. PubMed ID: 19176961 [TBL] [Abstract][Full Text] [Related]
12. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Schwarzschild MA Neurology; 2010 Nov; 75(21):1943-4; author reply 1944-5. PubMed ID: 21098412 [No Abstract] [Full Text] [Related]
13. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Montgomery EB Neurology; 2010 Nov; 75(21):1943; author reply 1944-5. PubMed ID: 21155188 [No Abstract] [Full Text] [Related]
14. [Treatment of degenerative dementia disorders--who should be treated?]. Hasselbalch SG; Kampmann JP Ugeskr Laeger; 2009 Mar; 171(10):802-5. PubMed ID: 19265606 [TBL] [Abstract][Full Text] [Related]
15. Why have we failed to achieve neuroprotection in Parkinson's disease? Olanow CW; Kieburtz K; Schapira AH Ann Neurol; 2008 Dec; 64 Suppl 2():S101-10. PubMed ID: 19127580 [TBL] [Abstract][Full Text] [Related]
16. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design. Rascol O Neurology; 2009 Feb; 72(7 Suppl):S51-8. PubMed ID: 19221315 [TBL] [Abstract][Full Text] [Related]
17. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Naoi M; Maruyama W Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610 [TBL] [Abstract][Full Text] [Related]
18. The delayed-start study design. D'Agostino RB N Engl J Med; 2009 Sep; 361(13):1304-6. PubMed ID: 19776413 [No Abstract] [Full Text] [Related]